The present study was performed to clarify the mechanism underlying the beneficial effects of lisinopril on chronic glomerulonephritis. Chronic glomerulonephritis was induced by a single injection of E30 monoclonal antibody (E30) recognizing Thy-1.1 antigen to unilaterally nephrectomized rats. E30 injection resulted in persistent massive proteinuria with a decrease in anionic charge sites on the glomerular basement membrane (GBM) at 8 weeks. Also, renal tissue from rats treated with E30 showed typical glomerulosclerosis and tubulointerstitial fibrosis. Lisinopril exerted a potent antiproteinuric effect and suppressed the progression of both glomerulosclerosis and tubulointerstitial fibrosis. Lisinopril recovered the reduced number of anionic charge sites on GBM, accounting for the positive action against massive proteinuria. Immunostaining for desmin revealed that lisinopril treatment prevented the injury of glomerular epithelial cells (GECs) occurring in the chronic nephritic stage. Also, the level of gene expression of transforming growth factor-β (TGF-β) and plasminogen activator inhibitor-1 (PAI-1) in the renal cortex were reduced, suggesting that lisinopril improved extracellular matrix (ECM) metabolism. These results indicated that proteinuria in Thy-1.1 antibody-induced chronic nephritis is associated with a decrease in anionic charge sites on GBM, and that the antiproteinuric effect of lisinopril is attributable to protection against GEC damage. Suppression of TGF-β and PAI-1 expression contributed to the preventive effect of lisinopril on ECM deposition in renal tissue.

Keywords:
Chronic Thy-1.1 nephritis, Lisinopril, Transforming growth factor-beta, Plasminogen activator inhibitor-1, Charge barrier
1.
Shinosaki T, Notoya M, Nomura Y, Miyai I, Kobayashi T, Kurihara H: Glomerular epithelial cell injury accelerates the progression of antibody-induced mesangial proliferative nephritis. Exp Nephrol, in press.
2.
Cheng QL, Orikawa M, Morioka T, Kawachi H, Chen XM, Oite T, Shimizu F: Progressive renal lesions induced by administration of monoclonal antibody 1-22-3 to unilaterally nephrectomized rats. Clin Exp Immunol 1995;102:181–185.
3.
Nakamura T, Obata J, Kimura H, Ohno S, Yoshida Y, Kawachi H, Shimizu F: Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 1999;55:877–889.
4.
Yayama K, Kawao M, Tujii H, Itoh N, Okamoto H: Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis. Eur J Pharmacol 1993;236:337–338.
5.
Tanaka R, Kon V, Yoshioka T, Ichikawa I, Fogo A: Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 1994;45:537–543.
6.
Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I: Serial micropuncture analysis of glomerular function in two rats models of glomerular sclerosis. J Clin Invest 1988;82:322–330.
7.
Anderson S, Diamond JR, Karnovsky MJ, Brenner BM; Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 1988;82:1757–1768.
8.
Marinides GN, Groggel GC, Cohen AH, Border WA: Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy. Kidney Int 1990;37:749–757.
9.
Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, Takahashi H, Sekino Y, Sasaki Y: Effects of captopril on heavy proteinuria in azotemic diabetes. N Engl J Med 1985;313:1617–1620.
10.
Shinosaki T, Takagawa I, Sunagawa N, Yonetani Y, Kurihara H: Dual effects of lisinopril on puromycin aminonucleoside nephrosis in unilaterally nephrectomized rats. Jpn J Pharmacol 1997;73:337–345.
11.
Ali S, Laping N, Fredrickson T, Contino L, Olson B, Anderson K, Brooks D: Angiotensin converting enzyme inhibition attenuates proteinuria and renal TGF-β1 mRNA expression in rats with chronic renal disease. Pharmacology 1998;57:20–27.
12.
Zoja C, Abbate M, Corna D, Capitanio M, Donadelli R, Bruzzi I, Oldroyd S, Benigni A, Remuzzi G: Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-β in experimental mesangioproliferative glomerulonephritis. Am J Kidney Dis 1998;31:453–463.
13.
Peters H, Border WA, Noble NA: Targeting TGF-β overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998;54:1570–1580.
14.
Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431–2437.
15.
Feener EP, Northrup JM, Aiello LP, King GL: Angiotensin II induces plasminogen inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995;95:1353–1362.
16.
Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A: Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 1997;51:164–172.
17.
Kriz W, Elger M, Nagata M, Kretzler M, Uiker S, Koeppen-Hagemann I, Tenschert S, Lemley KV: The role of podocytes in the development of glomerular sclerosis. Kidney Int 1994;45(suppl):S64–72.
18.
Kriz W, Gretz N, Lemley KV: Progression of glomerular disease: Is the podocyte the culprit? Kidney Int 1998;54:687–697.
19.
Floege J, Hackmann B, Kliem V, Kriz W, Alpers CE, Johnson RJ, Kuhn KW, Koch KM, Brunkhorst R: Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: A podocyte disease. Kidney Int 1997;51:230–243.
20.
Konkle B, Schuster SJ, Kelly MD, Harjes K, Hassett DE, Bohrer M, Tavassoli M: Plasminogen activator inhibitor-1 messenger RNA expression is induced in rat hepatocytes in vivo by dexamethasone. Blood 1992;79:2636–2642.
21.
Kivirikko K, Laitinen O, Prockop D: Modifications of a specific assay for hydroxyproline in urine. Anal Biochem 1967;19:249–255.
22.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265–270.
23.
Coimbra TM, Janssen U, Grone HJ, Ostendorf T, Kunter U, Schmidt H, Branbant G, Floege J: Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000;57:167–182.
24.
Wallenstein S, Zucker CL, Fleiss JL: Some statistical methods useful in circulation research. Circ Res 1980;47:1–9.
25.
Bagchus WM, Hoedemaeker PJ, Rozing J, Bakker WW: Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies: A sequential histological and ultrastructural study in the rat. Lab Invest 1986;55:680–687.
26.
Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, Yamanaka N: Recovery of damaged glomerular capillary network with endothelial cell apoptosis in experimental proliferative glomerulonephritis. Nephron 1998;79:206–214.
27.
Baker AJ, Mooney A, Hughes J, Lombardi D, Johnson RJ, Savill J: Mesangial cell apoptosis: The major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative glomerulonephritis. J Clin Invest 1994;94:2105–2116.
28.
Iruela-Arispe L, Gordon K, Hugo C, Duijvestijn AM, Claffey KP, Reilly M, Couser WG, Alpers CE, Johnson RJ: Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 1995;147:1715–1727.
29.
Floege J, Alpers CE, Sage H, Pritzl P, Gordon K, Johnson RJ, Couser WG: Markers of complement-independent glomerular visceral epithelial cell injury in vivo: Expression of antiadhesive proteins and cytoskeketal changes. Lab Invest 1992;67:486–497.
30.
Nagata M, Kriz W: Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int 1992;42:148–160.
31.
Yamamoto T, Noble NA, Miller DE, Border WA Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int 1994;45:916–927.
32.
Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor-beta1. Nature 1990;346:371–374.
33.
Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE: Stimulation of plasminogen activator inhibitor (PAI-1) in vivo by infusion of angiotensin II: Evidence of potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969–1973.
34.
Tomooka S, Border WA, Marshall BC, Noble NA: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 1992;42:1462–1469.
35.
Kanalas JJ, and Hopfer U: Effect of TGF-beta1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells. J Am Soc Nephrol 1997;8:184–192.
36.
Marti HP, Lee L, Kashgarian M, Lovett DH: Transforming growth factor-β1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. Am J Pathol 1994;144:82–94.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.